One of the most common questions about GLP-1 medications is also one of the most important: what happens when you stop? The honest answer, based on clinical trial data, is that most people regain a significant portion of their lost weight. But the full story is more nuanced than the headlines suggest—and understanding the timeline can help you plan smarter.
What the STEP 1 Extension Showed
The clearest data comes from the STEP 1 trial extension, published in Diabetes, Obesity and Metabolism in 2022. In the main trial, participants lost an average of 17.3% of their body weight over 68 weeks on semaglutide 2.4mg. When both the medication and the lifestyle intervention were discontinued, researchers tracked what happened over the following year.
The results were sobering but predictable:
| Timeline | Weight Status |
|---|---|
| Week 0 (start) | Baseline weight |
| Week 68 (stop meds) | -17.3% from baseline |
| Week 120 (1 year off) | -5.6% from baseline (regained ~11.6 pts) |
| Net regain | ~Two-thirds of weight lost |
Importantly, this wasn’t just a weight problem. Cardiometabolic improvements—blood pressure, cholesterol, blood sugar—also reverted toward baseline. The researchers’ conclusion was clear: obesity is a chronic condition, and ongoing treatment is generally required to maintain improvements.
A Meta-Analysis Confirms the Pattern
A 2025 systematic review and meta-regression that pooled data from six trials with 3,236 participants modeled the trajectory of weight regain after stopping GLP-1 medications. The findings: weight regain plateaus at approximately 75.6% of the weight lost during treatment. In other words, if you lost 40 pounds on a GLP-1, you could expect to regain roughly 30 pounds after stopping, with the regain slowing and eventually stabilizing.
The SURMOUNT-4 trial for tirzepatide showed a similar pattern. Patients who were switched from tirzepatide to placebo after 36 weeks of treatment regained a substantial portion of their weight, while those who continued treatment maintained or continued losing weight.
Real-World Data Tells a Better Story
Here’s where things get more encouraging. Clinical trials represent somewhat artificial conditions—patients stop both the medication and the structured lifestyle intervention simultaneously, creating a worst-case scenario. Real-world data suggests the picture is more favorable for many patients.
An EPIC Research analysis of over 20,000 patients who stopped semaglutide or liraglutide after losing at least 5 pounds found that more than half (55.7%) either maintained their weight or continued losing weight even a year after stopping. Only about 18% regained all their lost weight or more.
A 2026 study from Ohio and Florida similarly found that real-world weight regain after GLP-1 discontinuation was slower and less complete than clinical trial data predicted. Researchers attributed this to two factors: patients in trials typically lose more weight (creating a larger rebound potential) and are on treatment longer, and real-world patients often maintain some lifestyle changes even after stopping the medication.
Key Insight
The weight regain isn’t a failure of the medication or the patient. It’s a predictable biological response. Obesity involves hormonal and neurological set points that the body actively defends. When the medication is removed, those biological drives return. Understanding this is the first step toward planning for it.
The Regain Timeline: What to Expect
Based on the combined trial and real-world data, here’s a realistic timeline of what happens after stopping a GLP-1 medication:
Months 1-3: Appetite Returns
Within the first few weeks, most patients notice a gradual return of appetite and “food noise.” This is the brain’s reward system reactivating without the medication’s modulating effect. Hunger cues get louder. Portions creep up. The foods you could easily skip start calling again.
Months 3-6: Active Regain Phase
This is typically the period of fastest weight regain. Without the medication slowing gastric emptying and modulating appetite hormones, caloric intake naturally increases. The body’s metabolic rate, which may have downregulated during weight loss (adaptive thermogenesis), creates a calorie surplus even at what feels like normal eating.
Months 6-12: Regain Decelerates
Weight regain typically slows as the body approaches a new (higher) equilibrium. Most of the regain happens in the first 6-8 months, with diminishing velocity after that. By 12 months, the trajectory usually plateaus.
Months 12-18: New Plateau
Most patients settle at a weight that’s somewhere between their lowest GLP-1 weight and their pre-treatment starting weight. The exact landing point depends on lifestyle factors, metabolic health, and individual biology.
Strategies That Help: What the Evidence Supports
While complete prevention of weight regain is difficult without continued medication, several strategies can meaningfully slow or limit it:
- Maintain high protein intake: Protein is the most satiating macronutrient and helps preserve lean mass. Aim for 1.0-1.2g per kilogram of body weight daily, particularly if you built this habit during GLP-1 treatment.
- Resistance training: Preserving or building muscle mass keeps metabolic rate higher and improves body composition even if the scale moves up. Strength training 2-3 times per week is one of the most evidence-supported regain prevention strategies.
- Continue structured lifestyle support: The STEP 1 extension stopped both medication and lifestyle counseling. Maintaining regular accountability—whether through a provider, program, or tracking app—is associated with less regain.
- Dose reduction rather than abrupt stop: Some clinicians now recommend tapering to a lower maintenance dose rather than stopping entirely. While not extensively studied in trials, this approach aligns with how other chronic conditions are managed.
- Restart if needed: Weight regain after stopping is not a “failure.” Many patients cycle on and off GLP-1 medications based on weight, insurance, cost, or personal preference. This is a valid approach as long as dose titration is followed each time.
Why This Confirms Obesity Is a Chronic Disease
Weight regain after stopping GLP-1 medications is often framed as a negative. But it actually confirms something the medical community has known for years: obesity is a chronic condition driven by biology, not a temporary problem that can be “cured” with a course of treatment.
We don’t expect blood pressure to stay low after stopping blood pressure medication. We don’t expect blood sugar to remain controlled after stopping diabetes medication. The same logic applies to weight management medications.
The goal isn’t to take medication forever or to avoid it entirely—it’s to use all available tools strategically, with realistic expectations, to achieve the best health outcomes for your individual situation.
Sources
- Wilding JPH, et al. “Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension.” Diabetes Obes Metab. 2022;24:1553-1564.
- Aronne LJ, et al. “Continued Treatment with Tirzepatide for Maintenance of Weight Reduction.” JAMA. 2024;331:38-48. (SURMOUNT-4)
- EPIC Research. “Many Patients Maintain Weight Loss a Year After Stopping Semaglutide and Liraglutide.” January 2024.
- Systematic review and meta-regression: weight regain plateaus at 75.6%. medRxiv. 2025.
- Gasoyan H. Real-world weight regain data. AJMC. February 2026.